Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial

Smedt, Stefan De; Nkurikiye, John; Fonteyne, Yannick; Tuft, Stephen; Bacquer, Dirk De; Gilbert, Clare; Kestelyn, Philippe

doi:10.1136/bjophthalmol-2011-300415

Cited by 28 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(17) Similar to the present study, all the aforementioned studies found that the use of topical CsA 1%-2% was able to reduce the symptoms and signs of patients with VKC after two weeks of therapy. (6)(7)(8)(13)(14)(15)(16)(17) We noted that a burning sensation and foreign body sensation were more prominent in studies that used CsA in oil as compared to those that used an aqueous solution. Thus, such transient side effects might be due to the formulation and not the cyclosporine itself.…”

Section: A 2bsupporting

confidence: 78%

“…(16) In a double-blinded study, De Smedt et al compared the efficacy of topical CsA 2% and dexamethasone 0.1%. (17) After four weeks of therapy, the authors found that the reductions in the clinical scores and the improvements in visual acuity were similar in both treatments; however, foreign body sensation was more prominent with CsA therapy. (17) Similar to the present study, all the aforementioned studies found that the use of topical CsA 1%-2% was able to reduce the symptoms and signs of patients with VKC after two weeks of therapy.…”

Section: A 2bmentioning

confidence: 93%

“…(17) After four weeks of therapy, the authors found that the reductions in the clinical scores and the improvements in visual acuity were similar in both treatments; however, foreign body sensation was more prominent with CsA therapy. (17) Similar to the present study, all the aforementioned studies found that the use of topical CsA 1%-2% was able to reduce the symptoms and signs of patients with VKC after two weeks of therapy. (6)(7)(8)(13)(14)(15)(16)(17) We noted that a burning sensation and foreign body sensation were more prominent in studies that used CsA in oil as compared to those that used an aqueous solution.…”

Section: A 2bmentioning

confidence: 93%

“…(6)(7)(8)(13)(14)(15)(16)(17) Secchi et al reported cases of significant recoveries in clinical scores after the use of topical CsA 2% for two weeks. (6) 73% (n = 8) of patients in that study reported a transient burning sensation upon administration of topical CsA 2% and recurrences were reported 2-4 months after the cessation of therapy.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Yücel¹,

Ulus²

2016

smedj

View full text Add to dashboard Cite

RESULTSAt baseline, the median values of the symptom and sign scores were 10.0 (range 5.0-18.0) and 6.0 (range 2.0-13.0), respectively. At Week 4 of treatment with topical CsA 0.05%, the median values of the symptom and sign scores were 3.0 (range 0-14.0) and 3.0 (range 0-8.0), respectively. The reductions in the symptom and sign scores were statistically significant. The reduction in the need for corticosteroid was statistically significant by Week 12 of therapy. No significant side effects were reported.CONCLUSION Topical CsA 0.05%, which can help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC. Further studies are needed to determine the optimal duration of therapy and possibility of recurrence.

show abstract

Section: A 2bsupporting

confidence: 78%

Section: A 2bmentioning

confidence: 93%

Section: A 2bmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Yücel¹,

Ulus²

2016

smedj

View full text Add to dashboard Cite

show abstract

“…Overall, 69.3% were males, and the mean age of patient was 9.8 years (range, [7][8][9][10][11][12][13][14][15][16][17][18][19]. There was no statistically significant difference between the two groups in terms of sex or mean age (p > 0.05).…”

Section: Resultsmentioning

confidence: 99%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years

Kim

Quartilho

Larkin

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial

Abstract: There is no significant difference between the efficiency of topical CsA 2% and dexamethasone 0.1% for the management of acute VKC in Central Africa, but tolerance needs to be improved.

Cited by 28 publications

References 20 publications

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years

Contact Info

Product

Resources

About